Combating Antimicrobial Resistance (AMR)
Antimicrobial Resistance (AMR) has been defined by the World Health Organization as one of the top global public health crises. It occurs when bacteria, viruses, fungi, and parasites evolve to resist the effects of medications, rendering standard treatments ineffective. As a result, common infections become more difficult to treat, leading to prolonged illness, increased healthcare costs, and higher mortality rates. If left unaddressed, AMR could significantly undermine modern medicine, making routine procedures and minor injuries potentially life-threatening.
The growing spread of AMR is largely driven by the overuse and misuse of antibiotics in both healthcare and agriculture, coupled with a declining pipeline of new antimicrobial agents. With limited treatment alternatives and insufficient innovation in antibiotic development, the threat continues to escalate.
In response to this urgent global challenge, the CHB Group has co-founded Delta G Avaris GmbH, an innovative biomedical company dedicated to advancing personalized bacteriophage therapy. By bringing together interdisciplinary expertise, Delta G Avaris aims to develop novel, targeted approaches to combat resistant pathogens and reduce the spread of antimicrobial resistance.
Through its Life Science division, the CHB Group is committed to actively contributing to the fight against AMR, leveraging its expertise, network, and strategic partnerships to help preserve the effectiveness of antimicrobial therapies for future generations.
